{
    "Trade/Device Name(s)": [
        "Alere NT-proBNP for Alinity i"
    ],
    "Submitter Information": "Axis-Shield Diagnostics Limited",
    "510(k) Number": "K241176",
    "Predicate Device Reference 510(k) Number(s)": [
        "K092649"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "December 11, 2024",
    "Summary Letter Received Date": "December 11, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal pro B-type natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Alinity i system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)",
        "Immunoassay",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Alere NT-proBNP for Alinity i assay for quantitative measurement of NT-proBNP in serum and plasma using CMIA on Alinity i system to aid diagnosis of heart failure.",
    "Indications for Use Summary": "The Alere NT-proBNP for Alinity i assay is for the in vitro quantitative determination of NT-proBNP in human serum and plasma on the Alinity i system, used as an aid in the diagnosis of heart failure in patients with clinical suspicion of new onset or worsening heart failure in the emergency department.",
    "fda_folder": "Clinical Chemistry"
}